SOLIGENIX, INC. Deferred Costs, Current
SOLIGENIX, INC. (SNGX) had Deferred Costs, Current of $5.19 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredCostsCurrent · last filed 2026-08-07
- 2026-06-30: Deferred Costs, Current $5.19K.
- 2026-03-31: Deferred Costs, Current $98.72K.
- 2025-12-31: Deferred Costs, Current $18.54K.
- 2025-06-30: Deferred Costs, Current $31.68K.
| Period end | Deferred Costs, Current |
|---|---|
| 2026-06-30 | $5.19K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $98.72K 10-Q · filed 2026-05-08 |
| 2025-12-31 | $18.54K 10-Q · filed 2026-08-07 |
| 2025-06-30 | $31.68K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $43.84K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $103.85K 10-K · filed 2026-03-31 |
| 2024-09-30 | $126.39K 10-Q · filed 2024-11-08 |
| 2024-06-30 | $5.86K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $132.68K 10-Q · filed 2024-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |